<DOC>
	<DOCNO>NCT00232362</DOCNO>
	<brief_summary>This study do determine pioglitazone ( Actos ) helpful patient type 2 diabetes could possibly prevent harmful consequence cardiovascular disease diabetic patient .</brief_summary>
	<brief_title>Effect Pioglitazone Left Ventricular Diastolic Function Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Cross sectional population-based study indicate least one third patient congestive heart failure ( CHF ) normal near normal ejection fraction , think secondary diastolic dysfunction failure . The mortality rate among patient diastolic failure range 5-8 % annually , compare 10-15 % among patient systolic heart failure . The morbidity associate diastolic heart failure similar systolic heart failure . Several study show even simple Doppler evidence diastolic dysfunction independent risk factor development CHF cardiac death increase cause mortality . Several study indicate leave ventricular diastolic dysfunction ( LVDD ) represent early preclinical manifestation diabetic cardiomyopathy progress symptomatic heart failure . Recent study demonstrate 60 % asymptomatic , normotensive patient type 2 diabetes LVDD assess conventional echocardiography include response Valsalva maneuver . A recent study use conventional Doppler , valsalva maneuver , color M-mode echocardiography tissue doppler image assess diastolic dysfunction asymptomatic normotensive patient diabetes mellitus find diastolic dysfunction 75 % patient . Cardiovascular disease lead cause death patient type 2 diabetes mellitus . Although diabetic patient large number cardiovascular risk factor , like hyperlipidemia hypertension , diabetic cardiomyopathy occur independent risk factor . Recently animal model show LVDD may prevent chronic treatment peroxisome-proliferator-activated receptor gamma ( PPAR ) agonists , like thiazolidinediones , type 2 diabetic rat . Thiazolidinediones act PPAR , exact mechanism improve LVDD know . With background knowledge , want study effect Pioglitazone , PPAR agonist partial PPAR agonist , leave ventricular diastolic dysfunction type 2 diabetic human subject , study far . If therapy prove beneficial effect LVDD help prevent deleterious consequence diastolic dysfunction diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus ( DM ) 2 . Ages 18 65 year old 3 . Patients leave ventricular diastolic dysfunction ( LVDD ) ejection fraction ( EF ) &gt; 50 % 1 . Patients uncontrolled hypertension 2 . Patients active myocardial ischemia Canadian Cardiovascular Society ( CCS ) &gt; II know coronary artery disease ( CAD ) 3 . Patients atrial fibrillation 4 . Patients systolic heart failure 5 . Patients mitral regurgitation grade 2 6 . Patients restrictive cardiomyopathy 7 . Patients constrictive pericarditis 8 . Pregnant female patient 9 . Recent stroke 10 . Sepsis 11 . Liver enzymes 2.5 time normal 12 . Hemoglobin &lt; 11g/dl hematocrit &lt; 30 % 13 . Terminal cancer 14 . Patients fibrates group lipid lower agent 15 . Patients already pioglitazone rosiglitazone 16 . Patients place control group may currently take medication glitazones drug class . 17 . Current prior use Pioglitazone Rosiglitazone within precede 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>